Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 a phase 3 randomized controlled trial (RCT) Meeting Abstract
| Authors: | Scheid, C.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; Bahlis, N. J.; Moreau, P.; Solomon, S. R.; Delforge, M.; Berdeja, J.; Truppel-Hartmann, A.; Favre-Kontula, L.; Wu, F.; Piasecki, J.; Cook, M.; Giralt, S. |
| Abstract Title: | Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 a phase 3 randomized controlled trial (RCT) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 79 |
| End Page: | 80 |
| Language: | English |
| ACCESSION: | WOS:001091456900161 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: V540 -- Source: Wos |
